Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AAPG | 6-K | bearish | 5/10 | Ascentage Pharma reported H1 2026 results with revenue of RMB302.2M (+29.3% YoY), driven by product sales growth of 32.6 | Sep 17, 2026 |
| MIRA | PRESS-RELEASE | neutral | 3/10 | MIRA Pharmaceuticals announced submission of its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neur | Sep 17, 2026 |
| TELO | PRESS-RELEASE | neutral | 4/10 | Telomir Pharmaceuticals published peer-reviewed preclinical data showing Telomir-Zn improved visual function and reduced | Sep 17, 2026 |
| QNTM | 6-K | neutral | 3/10 | Quantum BioPharma announced that Rodman & Renshaw initiated analyst coverage with a BUY rating and an $8 price target. T | Sep 17, 2026 |
| COAG | PRESS-RELEASE | neutral | 4/10 | Hemab Therapeutics dosed the first healthy volunteer in a Phase 1 trial of HMB-003, a novel peptide-based antifibrinolyt | Sep 17, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine's Chief of Global Impact presented insights from the company's clinical trial at Yale and Johns Hopki | Sep 17, 2026 |
| INDV | 425 | neutral | 4/10 | Indivior declared an $8.13 per share special cash dividend contingent on closing its pending merger with Supernus. The d | Sep 17, 2026 |
| INDV | 8-K | neutral | 4/10 | Indivior declared an $8.13 per share special cash dividend contingent on closing its pending merger with Supernus Pharma | Sep 17, 2026 |
| AQST | 8-K | bullish | 7/10 | Aquestive Therapeutics announced the resubmission of its New Drug Application (NDA) to the FDA for Anaphylm (dibutepinep | Sep 17, 2026 |
| KMDA | 6-K | bullish | 6/10 | Kamada confirms sufficient KedRAB supply and manufacturing capacity to meet increased U.S. demand following a CDC Health | Sep 17, 2026 |
| TLSA | 6-K | neutral | 3/10 | Tiziana Life Sciences announced a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate | Sep 17, 2026 |
| INDV | PRESS-RELEASE | neutral | 4/10 | Indivior declared a special cash dividend of $8.13 per share, contingent on the closing of its previously announced merg | Sep 17, 2026 |
| TLSA | PRESS-RELEASE | neutral | 4/10 | Tiziana Life Sciences signed a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on | Sep 17, 2026 |
| IPHA | 6-K | bullish | 7/10 | Innate Pharma reported H1 2026 financial results showing a net loss of €19.6M (improved from €21.3M loss in H1 2025) wit | Sep 17, 2026 |
| IPHA | 6-K | mixed | 6/10 | Innate Pharma's H1 2026 6-K reports a net loss of €19.6m (improved from €21.3m in H1 2025) on revenue of €5.7m (up from | Sep 17, 2026 |
| IPHA | 6-K | bullish | 7/10 | Innate Pharma announces that its strategic partnership with Sobi for lacutamab is now effective, triggering a USD 75 mil | Sep 17, 2026 |
| SNY | 6-K | neutral | 4/10 | Sanofi announced a strategic partnership with Cheplapharm to transfer 20 mature medicines and three manufacturing sites | Sep 17, 2026 |
| NTHI | 8-K | bullish | 4/10 | CEO Amir Heshmatpour purchased 35,000 additional shares on September 15, 2026, for ~$115,400 at ~$3.30/share, extending | Sep 17, 2026 |
| KROS | EFFECT | neutral | 3/10 | Keros Therapeutics' shelf registration statement (S-3, File No. 333-298854) became effective on September 16, 2026. This | Sep 17, 2026 |
| SXTC | EFFECT | bearish | 5/10 | China SXT Pharmaceuticals' F-3 shelf registration (File No. 333-297305) became effective on September 16, 2026, allowing | Sep 17, 2026 |
| IPHA | PRESS-RELEASE | bullish | 6/10 | Innate Pharma's strategic partnership with Sobi for lacutamab is now effective after closing conditions were met, includ | Sep 16, 2026 |
| PBYI | CLUSTER | bearish | 4/10 | Two directors at Puma Biotechnology sold a combined $612K in open-market shares over a one-week window, with the bulk ($ | Sep 16, 2026 |
| TCRT | 8-K | neutral | 2/10 | Alaunos Therapeutics adopted Second Amended and Restated By-Laws on September 16, 2026, lowering the stockholder meeting | Sep 16, 2026 |
| LNTH | DEFA14A | neutral | 4/10 | Lantheus Holdings filed additional definitive proxy soliciting materials urging stockholders to vote FOR the approval of | Sep 16, 2026 |
| TVGN | SC 13D/A | neutral | 4/10 | Ryan H. Saadi filed Amendment No. 4 to his Schedule 13D, disclosing receipt of 8,000,000 restricted shares of Tevogen co | Sep 16, 2026 |
| INMB | 3 | neutral | 2/10 | James Sapirstein filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities benefici | Sep 16, 2026 |
| TVGN | SC 13D/A | neutral | 3/10 | Kirti Desai filed an amended Schedule 13D disclosing a grant of 750,000 restricted shares on September 14, 2026, increas | Sep 16, 2026 |
| AZN | COURT-RULING | neutral | 2/10 | The Tenth Circuit granted an unopposed motion to dismiss AstraZeneca's appeal as moot in its challenge to Colorado's 340 | Sep 16, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$6.7M of UTHR stock over Sept 11-14, 2026, alongside director Nilda Mesa's small sale. The s | Sep 16, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders at Arcutis Biotherapeutics sold a combined $364K in open-market sales over a week. The sales are modest rel | Sep 16, 2026 |